Enrollment completed for our Phase 2 clinical trial in Alport syndrome
ENYO Pharma is very proud to announce the successful completion of patient enrollment in ALPESTRIA-1, our Phase 2 clinical trial evaluating Vonafexor in Alport syndrome across the U.S. and Europe.
This major milestone was achieved with the last-patient-in dosed ahead of schedule. The study timelines were accelerated thanks to a tailored strategy based on a very strong and effective collaboration with our partners Natera and Accelsiors, all clinical sites in the US, France ans Spain with investigators,
7th CKD Summit – Chronic Kidney Disease Drug Development
17-19 March, 2025
Boston, MA
ENYO Pharma will attend the 7th Chronic Kidney Disease Drug Development Summit, an industry forum sharing cross-industry insight to bring effective therapies to patients suffering from kidney diseases expanding also to rare renal disorders.
https://ckd3-summit.com/
J.P. Morgan week and WuXi Global Forum 2025 in San Francisco
13-16 January, 2025
San Francisco, CA, USA
ENYO Pharma will in San Francisco for the J.P Morgan week to reconnect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
ENYO Pharma will also take the opportunity to host an executive roundtable at WuXi-Global-Forum-2025 on the 14th of January to share our progress in drug development with Vonafexor in kidney diseases.
4th Rare & Genetic Kidney Disease Drug Development Summit
10-12 December 2024
Boston, MA, USA
ENYO Pharma will attend for the first time the 4th Rare & Genetic Kidney Disease Drug Development Summit that will be held in Boston, USA. The event will bring together industries, academic KOLs, and patient advocacy nephrology communities to discuss acceleration of clinical advancements in orphan kidney disease populations.
ENYO Pharma will present the ongoing ALPESTRIA-1 Phase 2 clinical trial with Vonafexor in patients with Alport syndrome.
MOSAIC – the Global NASH/MASH Trialist Forum
24-25 October 2024
Washington DC, USA
ENYO Pharma is attending the MOSAIC – Global NASH Trialist Forum 2024. The goal of the meeting was to define new integrative Cardiovascular-Kidney-Liver-Metabolic (CKLM) trials together with cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders.
Latest Press Release 